Target intelligence / Profile preview

Claudin-16 (CLDN16)

Target
CLDN16
Molecular classification
Tight junction protein, Integral membrane protein, Ion channel (cation-selective, as part of complex), Other (Claudin family)
01

Overview

Claudin-16 is an integral membrane protein encoded by the CLDN16 gene and a core component of tight junctions in the kidney, specifically in the thick ascending limb of Henle’s loop. It forms paracellular channels (often in complex with Claudin-19) that selectively allow cations such as magnesium and calcium to pass between epithelial cells, crucial for maintaining electrolyte balance and generating the transepithelial voltage needed for passive reabsorption of these ions. Mutations or functional disruption of Claudin-16 impair paracellular magnesium and calcium resorption, leading to severe renal magnesium wasting, hypercalciuria, nephrocalcinosis, and progressive kidney failure—a condition known as familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC). No drugs directly target Claudin-16; its clinical significance is primarily as a genetic and functional biomarker for certain genetic forms of kidney disease[1][2][3][4].

Other names
Claudin 16CLDN16Paracellin-1PCLN1HOMG3hypomagnesemia 3 with hypercalciuria and nephrocalcinosisparacellin-1PCLN-1
02

Mechanism of action

Not applicable; no known drugs directly target Claudin-16. Theoretical mechanisms would involve modulation of paracellular permeability or ion channel formation within tight junctions.

03

Biological functions

Paracellular ion transport (magnesium and calcium)Maintenance of epithelial barrier function (tight junction)Establishment of transepithelial voltageRegulation of ion gradients in kidney tubules
04

Disease associations

Renal disease (hypomagnesemia with hypercalciuria and nephrocalcinosis, FHHNC)Kidney failureDisturbances in electrolyte homeostasis (especially magnesium and calcium)Possible role in renal cancer regulatory networks
05

Safety considerations

Disruption of Claudin-16 function causes massive magnesium loss, hypercalciuria, nephrocalcinosis, and progressive kidney disease[1][2][4].Therapeutic modulation could result in significant disturbances in renal electrolyte balance, raising risk for hypomagnesemia, kidney stones, and renal failure.
06

Biomarkers

Mutations in CLDN16 (diagnostic for familial hypomagnesemia with hypercalciuria and nephrocalcinosis, FHHNC)Promoter/enhancer methylation or miRNA regulation (potential research biomarkers for gene expression and kidney disease risk)[4]

Beyond the preview

Go deeper on Claudin-16 (CLDN16).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Claudin-16 (CLDN16).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call